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Silicosis is an occupational lung disease for which no effective therapy exists. We
hypothesized that bosutinib, a tyrosine kinase inhibitor, might ameliorate inflammatory
responses, attenuate pulmonary fibrosis, and thus improve lung function in experimental
silicosis. For this purpose, we investigated the potential efficacy of bosutinib in
the treatment of experimental silicosis induced in C57BL/6 mice by intratracheal
administration of silica particles. After 15 days, once disease was established, animals
were randomly assigned to receive DMSO or bosutinib (1 mg/kg/dose in 0.1 mL 1%
DMSO) by oral gavage, twice daily for 14 days. On day 30, lung mechanics and
morphometry, total and differential cell count in alveolar septa and granuloma, levels of
interleukin (IL)-1β, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-4, transforming
growth factor (TGF)-β, and vascular endothelial growth factor in lung homogenate,
M1 and M2 macrophages, total leukocytes, and T cells in BALF, lymph nodes, and
thymus, and collagen fiber content in alveolar septa and granuloma were analyzed. In
a separate in vitro experiment, RAW264.7 macrophages were exposed to silica particles
in the presence or absence of bosutinib. After 24 h, gene expressions of arginase-1,
IL-10, IL-12, inducible nitric oxide synthase (iNOS), metalloproteinase (MMP)-9, tissue
inhibitor of metalloproteinase (TIMP)-1, and caspase-3 were evaluated. In vivo, in silicotic
animals, bosutinib, compared to DMSO, decreased: (1) fraction area of collapsed alveoli,
(2) size and number of granulomas, and mononuclear cell granuloma infiltration; (3)
IL-1β, TNF-α, IFN-γ, and TGF-β levels in lung homogenates, (4) collagen fiber content
in lung parenchyma, and (5) viscoelastic pressure and static lung elastance. Bosutinib
also reduced M1 cell counts while increasing M2 macrophage population in both lung
parenchyma and granulomas. Total leukocyte, regulatory T, CD4+, and CD8+ cell
counts in the lung-draining lymph nodes also decreased with bosutinib therapy without
affecting thymus cellularity. In vitro, bosutinib led to a decrease in IL-12 and iNOS
and increase in IL-10, arginase-1, MMP-9, and TIMP-1. In conclusion, in the current
model of silicosis, bosutinib therapy yielded beneficial effects on lung inflammation and
remodeling, therefore resulting in lung mechanics improvement. Bosutinib may hold
promise for silicosis; however, further studies are required.
Keywords: tyrosine kinase inhibitor, lung fibrosis, macrophage polarization, regulatory T cells, lymphocytes, lung
mechanics
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INTRODUCTION
Silicosis is a chronic occupational pulmonary disease caused by
long-term inhalation of silica dust (Laney and Attfield, 2010;
Suarthana et al., 2011; Lopes-Pacheco et al., 2014). Once these
particles are inhaled, they can trigger persistent inflammation
of the alveoli and further pulmonary fibrosis, resulting in a
cycle of lung damage (Thakur et al., 2009). Silica particles
induce macrophage activation, with consequent recruitment of
lymphocytes and neutrophils, as well as fibroblasts, which are
implicated in progressive tissue fibrosis (Borges et al., 2001;
Rimal et al., 2005; Greenberg et al., 2007). The injury is usually
irreversible and disabling, due to the formation of granulomas
that reduce the area available for gas exchange and thus impair
lung function (Leung et al., 2012; Kawasaki, 2015; Cruz et al.,
2016). Silicosis remains a prevalent health problem worldwide,
particularly in developing nations (Craighead et al., 1988; Leung
et al., 2012). To date, no conventional therapy is able to alter
the progressive course of the disease or reverse lung fibrosis
effectively.
The Src family of tyrosine kinases (TKs) has been shown
to play key roles in oxidant-mediated signal transduction in
macrophages (Khadaroo et al., 2003; Kang et al., 2006) and
lymphocytes (Salmond et al., 2009). These kinases interact with
various signal transduction pathways downstream of different
surface receptors, coordinating critical cellular processes such as
proliferation and differentiation, cell survival and metabolism,
cell migration, apoptosis, cytoskeletal rearrangement, and
immune response (Thomas and Brugge, 1997; Okutani et al.,
2006; Ahluwalia et al., 2010). Thus, they play an important
regulatory role in almost all aspects of cell biology (Manning
et al., 2002). Activation of protein kinases is known to
occur in a variety of diseases, including cancer, inflammatory
disorders (Summy and Gallick, 2003; Johnson and Gallick,
2007; Hu et al., 2008; Li, 2008; Zarbock and Ley, 2011; Liu
et al., 2014; Kong et al., 2015; Ozanne et al., 2015), and
fibrotic processes (Chaudhary et al., 2007; Grimminger et al.,
2010). Because of its widespread involvement in numerous
physiological and pathological processes (Thomas and Brugge,
1997; Dehm and Bonham, 2004; Lemmon and Schlessinger,
2010; Keller and Brummendorf, 2012), it is not surprising
that the Src signaling pathway has been successfully targeted
by multiple drug-discovery programs (Hopkins and Groom,
2002; Overington et al., 2006) and has been regarded as a
promising new therapeutic approach for lung diseases (Richeldi
et al., 2011; Oliveira et al., 2015; Cruz et al., 2016; da Silva
et al., 2016) due to its anti-inflammatory and anti-fibrotic
effects. In this line, nintedanib, an intracellular inhibitor that
targets multiple tyrosine kinases, reduced lung-function decline
and acute exacerbations in patients with idiopathic pulmonary
fibrosis (Richeldi et al., 2011). Our group reported that dasatinib,
a second-generation tyrosine kinase inhibitor, is regarded as a
potential therapeutic strategy for the treatment of silicosis (Cruz
et al., 2016).
Bosutinib is a third-generation oral multi-target inhibitor of
tyrosine kinases (Remsing Rix et al., 2009), including the Src/Abl
family, originally developed as a cancer treatment (Puttini
et al., 2006; Vultur et al., 2008; Goldenberg, 2012; Amsberg
and Koschmieder, 2013) and associated with fewer side effects
than first- and second-generation inhibitors (Cortes et al., 2011;
Khoury et al., 2012).
In this study, we hypothesized that bosutinib might reduce
the inflammatory response, halt the progression of pulmonary
fibrosis, and contribute to the improvement of lung function
in a murine model of silicosis. For this purpose, we have
investigated the mechanisms of action of bosutinib and their
potential experimental efficacy in the treatment of silicosis.
MATERIALS AND METHODS
The Ethics Committee of the Health Sciences Center, Federal
University of Rio de Janeiro, approved this study (CEUA-CCS-
012/14). All animals received humane care in compliance with
the “Principles of Laboratory Animal Care” formulated by the
National Society for Medical Research and the U.S. National
Research Council “Guide for the Care and Use of Laboratory
Animals,” and all efforts were made to minimize suffering.
Animal Preparation and Experimental
Protocol
A total of 64 C57BL/6 female mice (age 8–12 weeks, weight 24.1
± 0.4 g) were assigned to two main groups: control (CTRL)
and silicosis (SIL). Mice in the CTRL group received 50µL
sterile saline intratracheally (i.t.), while animals in the SIL group
received a silica particle suspension (20mg in 50 µL saline
i.t.). Fifteen days after administration of saline or silica, animals
were randomized to receive dimethyl sulfoxide (1% DMSO in
saline solution, 100 µL, oral gavage; CTRL-DMSO and SIL-
DMSO groups) or bosutinib (BOS 1 mg/kg body weight in 1%
DMSO, 100 µL, oral gavage; CTRL-BOS and SIL-BOS groups),
twice daily for 14 days (Figure 1). As bronchoalveolar lavage
may affect lung morphological analysis and compromise lung
function, 32 female C57BL/6 mice were used to evaluate lung
mechanics and histology (n = 8/group), and another 32 female
animals were used for analysis of total and differential cell
counts in bronchoalveolar lavage fluid (BALF), thymus tissue,
and lung-draining lymph nodes (n= 8/group). All mice had their
clinical score evaluated at day at the harvest day (Araujo et al.,
2010). The score consisted of analyzing the following parameters:
presence of piloerection, altered respiration rate, fecal alteration,
lacrimation/eyelid changes, contraction of the abdomen, lack
of strength when grasping, change in body temperature, alert
response (scape after touch), exploration of the environment and
compromised locomotor activity. For every parameter present,
we gave 1 point, and in the absence of the parameter analyzed,
no points were given. Then, the points were computed for each
mouse.
Lung Mechanics
Twelve hours after the last dose of bosutinib, 32 animals were
sedated with diazepam [(Cristália, Itapira, SP, Brazil), 1mg
intraperitoneally (i.p.)], anesthetized with thiopental sodium
[(Cristália, Itapira, SP, Brazil) 20 mg/kg i.p.], tracheotomized,
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FIGURE 1 | Study design. Sixty-four C57BL/6 female mice were divided into two groups: control (CTRL, n = 32) received sterile saline (50 µL) intratracheally (i.t.),
while silicosis group (SIL, n = 32) received silica particles (20mg in 50 µL saline, i.t.). Fifteen days after disease induction, the animals were randomized to receive
dimethyl sulfoxide (DMSO 1% in saline solution, 100 µL, oral gavage) or bosutinib (BOS 1 mg/kg body weight in DMSO 1%, 100 µL, oral gavage).
paralyzed with vecuronium bromide [(Cristália, Itapira, SP,
Brazil) 0.005 mg/kg intravenously (i.v.)], and ventilated with
a constant-flow ventilator (Samay VR15; Universidad de la
Republica, Montevideo, Uruguay) set as follows: respiratory rate
= 100 breaths/min, tidal volume (VT) = 0.2 mL, and fraction
of inspired oxygen (FiO2) = 0.21. The anterior chest wall
was surgically removed and a positive end-expiratory pressure
(PEEP) of 2 cmH2O applied. Airflow and tracheal pressure
(Ptr) were measured. In an open chest preparation, Ptr reflects
transpulmonary pressure (PL). After a 10-min ventilation period,
static lung elastance (Est,L) and lung resistive (1P1,L) and
viscoelastic/inhomogeneous pressures (1P2,L) were measured
using the end-inflation occlusion method (Bates et al., 1985).
All data were analyzed using ANADAT software (RHT-InfoData,
Inc., Montreal, Quebec, Canada).
Histological Analysis
Immediately after determination of lung mechanics, a
laparotomy was performed and heparin (Cristália, Itapira,
SP, Brazil) 1,000 IU was injected into the vena cava. The trachea
was clamped at end-expiration (PEEP = 2 cmH2O), and the
vena cava and abdominal aorta were sectioned, leading to a
massive hemorrhage and euthanasia by terminal bleeding. The
left lung was then removed, flash-frozen by immersion in liquid
nitrogen, fixed with Carnoy’s solution and paraffin-embedded.
Sections (4 µm thick) were cut and stained with hematoxylin
and eosin. Lung morphometry analysis was performed using
an integrating eyepiece with a coherent system consisting of
a grid with 100 points and 50 lines of known length coupled
to a conventional light microscope (Olympus BX51, Olympus
Latin America-Inc., São Paulo, Brazil). The fraction area of lung
occupied by collapsed or normal alveoli was determined by the
point-counting technique (Weibel, 1990) across 10 random,
non-coincident microscopic fields at 200× magnification.
Briefly, points falling on collapsed or normal pulmonary areas
were counted and divided by the total number of points in each
microscopic field (Weibel, 1990). Additionally, the fraction area
of granuloma was determined in 20 random non-coincident
microscopic fields, at 400× magnification (Maron-Gutierrez
et al., 2011; Lopes-Pacheco et al., 2013). Total cells and
mononuclear and polymorphonuclear cell subpopulations
in the alveolar septa and granuloma tissue were evaluated at
1,000×magnification in 10 random microscopic fields. Collagen
fibers (Picrosirius polarization method) were computed in the
alveolar septa and granuloma at 400× magnification using
Image-Pro Plus 6.3 software (Media Cybernetics, Silver Spring,
MD, USA; Maron-Gutierrez et al., 2011; Chen et al., 2013).
Bronchi and blood vessels were carefully avoided during the
measurements. The area occupied by fibers was determined by
digital densitometric recognition. The results were expressed as
the fraction area occupied by collagen fibers in the alveolar septa
or in granuloma. An expert in lung pathology blinded to the
experimental protocol performed all histological analyses.
Immunohistochemistry for Macrophages
Silanized slides containing 3-µm-thick tissue sections were
deparaffinized in hot xylol (60–65◦C) in an incubator for 10
min, then washed three times in cold xylol. For rehydration,
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FIGURE 2 | Lung mechanics. Static lung elastance (Est,L) (A), resistive (1P1) (B), and viscoelastic pressure (1P2) (C). White bars, DMSO gray bars, BOS. Values
are means + SD of eight animals per group. *Significantly different from CTRL-DMSO group (p < 0.05). **Significantly different from SIL-DMSO (p < 0.05).
FIGURE 3 | Lung histology. Representative photomicrographs (light
microscopy) of lung parenchyma stained with hematoxylin and eosin from
CTRL-DMSO, CTRL-BOS, SIL-DMSO, and SIL-BOS animals. G, granuloma.
Arrows denote areas of alveolar collapse. Original magnification 200×. Scale
bars = 200 µm.
slides were washed down through a graded ethanol series (100,
95, and 70%) at 70◦C, rinsed successively in tap water and
deionized water, and left in phosphate buffer (pH 7.4). Samples
were then exposed to citric acid solution (10mM pH 6.0) at
high temperatures in a pressure cooker, for 1min, for antigenic
site recovery. Endogenous peroxidase was blocked by hydrogen
peroxide 10 v/v (3%) and washed with phosphate-buffered saline
(PBS). Unspecific proteins were blocked by slides immersion in
5% casein in phosphate buffer (pH 7.4) for 5min. The slides
were incubated with primary anti-(NOS)-2 antibody (1:100,
Biorbyt Ltd., Cambridge, UK) for M1 macrophages and anti-
CD163 antibody (1:100, Biorbyt Ltd., Cambridge, UK) for M2
macrophages, for 24 h. Slides were then incubated with a
secondary antibody (Easylink One polymer HRP, EasyPath, São
Paulo, Brazil) and diaminobenzidine (DAB) as a chromogen
(Sigma-Aldrich). Subsequently, slides were counter-stained with
Harris hematoxylin.
Quantification of Mediators in Lung
Homogenates
Levels of interleukin (IL)-1β, tumor necrosis factor (TNF)-α,
interferon (IFN)-γ, IL-4, transforming growth factor (TGF)-β,
and vascular endothelial growth factor (VEGF) were quantified
by ELISA in the lung homogenate. Lung tissue was homogenized
in lysis buffer [PBS 1x, triton X 0.01%, 1× Roche protease
inhibitor cocktail (Roche Diagnostic, Mannheim, Germany)]
using a glass Potter homogenizer with Teflon piston. The
total amount of cytokines was quantified according to the
manufacturer’s protocol (Duo Set, R&D Systems, Minneapolis,
MN, USA) and normalized to the total content of protein
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quantified by Bradford’s reagent (Sigma-Aldrich, St Louis, MO,
USA).
Total and Differential Cell Counts in
Bronchoalveolar Lavage Fluid, Mediastinal
Lymph Nodes, and Thymus Tissue
Thirty-two mice were euthanized for evaluation of total and
differential cellularity in bronchoalveolar lavage fluid (BALF),
mediastinal lymph nodes, and thymus. First, animals were
euthanized with a lethal dose (100 mg/kg) of thiopental sodium
(Cristália). The trachea was immediately cannulated, then flushed
three times with 0.4 mL of 1% PBS solution in order to obtain
BALF cells. BALF was then centrifuged (239 g, 10 min) and
the cell pellet was resuspended in PBS. Cells from the lung-
draining mediastinal lymph nodes and thymus were obtained
through mechanical maceration of the organs. Total leukocytes
were quantified with Türk solution in a Neubauer chamber.
T cells recovered from BALF, lymph nodes, and thymus
were distinguished after staining with anti-mouse CD4 PE
(eBioscience, SanDiego, CA, USA) for T helper cells, anti-mouse
CD8 PECy5 (eBioscience, SanDiego, CA, USA) for T cytotoxic
cells, and anti-mouse anti-CD4-FITC, anti-mouse anti-CD25-
APC, and anti-mouse anti-Foxp3-PE (Treg kit, eBioscience,
SanDiego, CA, USA) for T regulatory (Treg) cells. These
cells were evaluated in a FACSCalibur flow cytometer (Becton
Dickinson Biosciences, San Jose, CA, USA) and analyzed in
FlowJo 7.6.5 software (TreeStarInc., Ashland, OR, USA).
TABLE 1 | Lung morphometry.
Group Normal (%) Collapse (%) Mononuclear cells (%) Neutrophils (%) Total cells (%)
CTRL DMSO 98.7 ± 0.8 1.3 ± 0.8 14.4 ± 0.8 2.8 ± 0.1 17.2 ± 0.8
BOS 97.7 ± 1.6 2.3 ± 1.6 14.6 ± 2.2 2.8 ± 0.4 17.4 ± 2.2
SIL DMSO 79.7 ± 6.4* 20.3 ± 6.4* 32.3 ± 3.5* 5.4 ± 0.8* 37.7 ± 3.7*
BOS 89.6 ± 3.5*,** 10.4 ± 3.5*,** 27.3 ± 1.5*,** 3.9 ± 0.8*,** 31.2 ± 2.0*,**
Fraction area of normal alveoli, collapsed alveoli, and lung hyperinflation. Values are mean ± SD of 10 animals per group. In the control (CTRL) group, mice received sterile saline (50 µL)
intratracheally (i.t.), while in the silicosis group, animals received a silica particle suspension (20mg in 50 µL saline, i.t.). Fifteen days after administration of saline or silica, animals were
randomized to receive dimethyl sulfoxide (DMSO 1% in saline solution, 100 µL, oral gavage—CTRL-DMSO and SIL-DMSO groups) or bosutinib (BOS 1 mg/kg body weight in DMSO
1%, 100 µL, oral gavage—CTRL-BOS and SIL-BOS groups), twice a day for 14 days. *Significantly different from CTRL-DMSO. **Significantly different from SIL-DMSO (p < 0.05).
FIGURE 4 | Fraction area of granuloma in lung parenchyma (A) and percent total cell count (B), mononuclear cells (C), and neutrophils (D). All values were
computed in 10 random, non-coincident fields of views per mouse. Boxes show the interquartile (25–75%) range, whiskers encompass the range
(minimum–maximum), and horizontal lines represent median values of 8 animals per group. **Significantly different from SIL-DMSO (p < 0.05).
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In vitro Analysis of Macrophages
RAW264.7 cells, a mouse peritoneal macrophage cell line, were
obtained from American Type Culture Collection (Rockville,
MD, USA) and maintained in culture using Dulbecco’s Modified
Eagle Medium (DMEM)—High Glucose supplemented with 10%
fetal bovine serum, 1,000 U/mL penicillin/streptomycin, and
2mML-glutamine (Invitrogen, Life Technologies Grand Isle, NY,
USA). Cells were plated in six-well plates (106 cells/well) for 48
h. Fresh medium was then substituted, and cells were exposed
to silica particles (100 µg per mL medium) for 24 h (21) or
left incubated with regular medium. The supernatant was then
removed, and cells were washed with 1X PBS and then incubated
with bosutinib (100 ng/mLmedium) or regular medium for 24 h.
Once again, the supernatant was removed, cells washed with PBS,
lifted using 2.5% Trypsin/EDTA (Invitrogen Life Technologies
Grand Isle, NY, USA), and pelleted by centrifugation (600 g for
5 min).
A quantitative real-time reverse transcription polymerase
chain reaction (PCR) was performed to measure mRNA
expression of inducible nitric oxide synthase (iNOS), arginase-
1, interleukin (IL)-10, IL-12, metalloproteinase (MMP)-9, tissue
inhibitor of metalloproteinase (TIMP)-1, and caspase-3. Cells
were lysed for RNA extraction through the RNeasy Plus
Mini Kit (Qiagen, Valencia, CA, USA), following manufacturer
recommendations. The total RNA concentration was measured
by spectrophotometry in a Nanodrop ND-1000 system. First-
strand cDNA was synthesized from total RNA using an M-MLV
Reverse Transcriptase Kit (Invitrogen Life Technologies Grand
Isle, NY, USA). RelativemRNA levels weremeasured with a SYBR
Green detection system using ABI 7,500 real-time PCR (Applied
Biosystems, Foster City, CA, USA). All samples were measured
in triplicate. The relative level of each gene was calculated as
the ratio of the study gene to the control gene (acidic ribosomal
phosphoprotein P0 [36β4]) and given as the fold change relative
to RAW cells incubated with regular medium. The following
PCR primers were used: IL-10: forward 5′ TCC CTG GGT GAG
AAG CTG-3′, reverse 5′ GCT CCA CTG CCT TGC TCT-3′;
Arginase-1: forward 5′ GCT CAG GTG AAT CGG CCT TTT-
3′, reverse 5′ TGG CTT GCG AGA CGT AGA C-3′; IL-12:
forward 5′ AAC GCA GCA CTT CAG AAT CA-3′, reverse
5′ GAA GCA GGA TGC AGA GCT TC-3′; iNOS: forward 5′
CTTCAGGTATGCGGTATTGG-3′, reverse 5′ CAT GGT GAA
CAC GTT CTT GG-3′; MMP-9: forward 5′ AGT CCG GCA
GAC AAT CCT T-3′, reverse 5′ CCC TGT AAT GGG CTT CCT
C-3′; TIMP-1: forward 5′ CAT GGA AAG CCT CTG TGG AT-
3′, reverse 5′ GGG GAG ATG TGG ACT GTG A-3′; caspase-3:
forward 5′ TAC CGG TGG AGG CTG ACT-3′, reverse 5′-GCT
GCA AAG GGA CTG GAT-3′; 36β4: forward 5′ CAA CCC AGT
FIGURE 5 | Macrophage polarization: M1 and M2. Representative immunohistochemistry photomicrographs of M1 (iNOS-positive) and M2 (arginase-positive)
macrophages (right panels). Quantification of M1 (A) and M2 (B) (global score: severity × extension) in lung tissue of CTRL-DMSO, CTRL-BOS, SIL-DMSO, SIL-BOS.
Arrows denote M1 or M2 cells. White bars, DMSO; gray bars, BOS. Boxes show the interquartile (25–75%) range, whiskers encompass the range
(minimum–maximum), and horizontal lines represent median values of 8 animals per group. *Significantly different from CTRL-DMSO group (p < 0.05). **Significantly
different from SIL-DMSO (p < 0.05).
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TCT GGA GAA AC-3′, reverse 5′ GTT CTG AGC TCC CAC
AGTGA-3′.
Statistical Analysis
Sample size calculation for testing the primary hypothesis (static
lung elastance increased in the SIL group) was based on previous
measurements (Lopes-Pacheco et al., 2013; Cruz et al., 2016)
and on pilot studies. A sample size of 8 animals per group
(considering one animal as dropout) was deemed to provide
the appropriate power (1–β = 0.8) to identify significant (α =
0.05) differences in static lung elastance between SIL animals and
those treated with BOS, with an effect size d = 1.9, a two-sided
test, and a sample size ratio = 1 (G∗Power 3.1.9.2, University
of Düsseldorf, Germany). The normality of data (Kolmogorov–
Smirnov test with Lilliefors’ correction) and the homogeneity of
variances (Levene median test) were tested. Parametric data are
expressed as mean± SD, and non-parametric data as median and
interquartile range (IQR). To analyze all parameters associated
with granuloma, the Mann–Whitney test for non-parametric
data was used. Two-way ANOVA following Bonferroni’s post-hoc
test was used to compare all other parameters. P-values of 0.05
or less were considered significant. All tests were performed in
the GraphPad Prism v6.0 statistical software package (GraphPad
Software, La Jolla, CA, USA).
RESULTS
No animals died during experiments. Groups CTRL-DMSO and
CTRL-BOS presented score 0 [0–0], SIL-DMSO presented a score
of 0 [0–1], and SIL-BOS presented a score of 0 [0–1] with no
FIGURE 6 | Levels of cytokines and growth factors. Quantification of protein levels of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-4,
transforming growth factor (TGF)-β, and vascular endothelial growth factor (VEGF) quantified by ELISA in the lung homogenate. Black circle, DMSO; black square,
BOS. Symbols represent individual animals. Lines represent median (interquartile range) of 8 animals per group. *Significantly different from C-DMSO (p < 0.05).
**Significantly different from SIL-DMSO (p < 0.05).
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statistical difference between groups. No statistical differences
were observed between animas concerning their body weight
during experiments. At day 0, animals weighted 24.1 ± 0.4 g. At
day 15, CTRL animals weighted 24.9 ± 0.6 g, and SIL animals
weighted 24.6 ± 0.7. At day 30, animals CTRL-DMSO weighted
26.3 ± 1.0 g, CTRL-BOS weighted 26.4 ± 0.8 g, SIL-DMSO
weighted 25.5± 0.7 g, and SIL-BOS weighted 25.8± 0.5 g.
Lung Mechanics
Est,L (Figure 2A), 1P1,L (Figure 2B), and 1P2,L (Figure 2C)
did not differ significantly between the CTRL-DMSO and CTRL-
BOS groups. Est,L,1P1,L, and1P2,L were higher in SIL-DMSO
compared to CTRL-DMSO animals (p = 0.0034, p = 0.0011,
and p < 0.001, respectively). Bosutinib treatment reduced Est,L
and1P2,L significantly in animals with silicosis (p= 0.0054 and
p = 0.03, respectively); however, no significant differences were
observed regarding1P1,L (p= 0.61; Figure 2).
Lung Morphometry and Inflammation
Photomicrographs of lung parenchyma in both the CTRL-DMSO
and CTRL-BOS groups showed preserved pulmonary structure
(Figure 3). SIL-DMSO animals exhibited areas of granuloma
with different sizes, associated with alveolar collapse, thickened
alveolar septa with cell infiltration, and interstitial edema
compared to CTRL-DMSO. After treatment with bosutinib, the
fraction area of granuloma was reduced further in SIL-BOS
compared to SIL-DMSO, and there was less alveolar collapse and
interstitial edema (Figure 3).
SIL-DMSO was associated with a significant increase in the
fraction area of alveolar collapse, fraction area of mononuclear
cells, neutrophil count, and total cell count in the alveolar septa
compared with CTRL-DMSO (p < 0.0001). Bosutinib treatment
reduced the fraction area of alveolar collapse (p = 0.002), the
fraction area of mononuclear cells (p= 0.0005), neutrophils (p=
0.0001), and total cells (p< 0.0001) in silicotic animals compared
to SIL-DMSO (Table 1).
Bosutinib therapy reduced the fraction area of granuloma
(p = 0.01) (Figure 4A), as well as total cell counts (p =
0.03; Figure 4B) and mononuclear cell counts (p = 0.003)
in granulomatous nodules (Figure 4C). No significant changes
were observed in neutrophil counts within granuloma tissue
(Figure 4D).
The M1 (NOS2-positive) and M2 (CD168-positive)
subpopulations were quantified in alveolar septa and granuloma
FIGURE 7 | Expression of interleukin (IL)-10 (A), arginase (Arg)-1 (B), IL-12 (C), inducible nitric oxide synthase (iNOS) (D), metalloproteinase (MMP)-9 (E), tissue
inhibitor of metalloproteinase (TIMP) (F), and caspase-3 (G) in macrophages exposed to saline or silica and treated with DMSO or bosutinib (BOS). White bars, DMSO;
gray bars, BOS. Values are means + SD of 8 animals per group. *Significantly different from C-DMSO (p < 0.05). **Significantly different from SIL-DMSO (p < 0.05).
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FIGURE 8 | Total inflammatory cell counts in bronchoalveolar lavage fluid (BALF) (A), lymph node (B), and thymus tissue (C). Black circle, DMSO; black
square, BOS. Symbols represent individual animals. Lines represent median (interquartile range) of 6 or 8 animals per group. *Significantly different from C-DMSO (p <
0.05). **Significantly different from SIL-DMSO (p < 0.05).
for assessment of extension and severity (Figure 5). The
product of these values was computed as the M1 or M2 global
score. Bosutinib did not affect M1 or M2 global score in
CTRL animals. M1 (pro-inflammatory) macrophages were
increased in SIL-DMSO animals compared to CTRL-DMSO (p
= 0.0286) and reduced in SIL-BOS compared to SIL-DMSO
(p = 0.0265; Figure 5A). There were no significant changes in
M2 (anti-inflammatory) macrophage subpopulations between
CTRL-DMSO and SIL-DMSO groups (Figure 5B). However,
there was a significant increase in M2 macrophages in SIL-BOS
compared to CTRL-BOS (p= 0.025) and SIL-DMSO (p= 0.029)
(Figure 5B).
Levels of IL-1β, TNF-α, IFN-γ, and TGF- β were increased
in lung homogenates of SIL-DMSO compared to CTRL-DMSO
(p = 0.0006; p = 0.0448; p = 0.0372; p < 0.0001, respectively).
Treatment with bosutinib reduced levels of IL-1β, TNF-α, and
IFN-γ (p = 0.0124, p = 0.0295, p = 0.0192, respectively) and
minimized levels of TGF-β (p= 0.0258) compared to SIL-DMSO.
No differences were observed in IL-4 and VEGF levels among
groups (Figure 6).
In vitro Analysis
Macrophages exposed to silica and treated with bosutinib showed
an increase in expression of IL-10, and anti-inflammatory
cytokine (p = 0.0004; Figure 7A), and arginase-1, a classical
marker of M2 macrophages (p = 0.0002; Figure 7B), compared
to those exposed to silica and treated with DMSO; reduced
expression of the pro-inflammatory cytokine IL-12 (p = 0.007;
Figure 7C) and of iNOS, a marker of M1 macrophages (p =
0.019), was also observed (Figure 7D). In macrophages exposed
to silica and treated with DMSO, IL-12 (p = 0.003; Figure 7C),
and iNOS (p = 0.017) expressions (Figure 7D) were increased
compared to macrophages not exposed to silica but treated with
DMSO. In addition, there was increased expression of MMP-
9 (p = 0.047; Figure 7E) and TIMP-1 (p = 0.026; Figure 7F)
in macrophages exposed to silica and treated with bosutinib
compared to those treated with DMSO. No significant differences
among groups were observed regarding expression of the pro-
apoptotic mediator caspase-3 (Figure 7G).
Flow Cytometry
Leukocyte counts were higher in the BALF (p = 0.02) and lung-
draining lymph nodes (p = 0.015) of SIL-DMSO compared
to CTRL-DMSO animals (Figures 8A,B). In SIL-BOS animals,
leukocyte counts in the lung-draining lymph nodes were lower
than those of SIL-DMSO animals (p = 0.005; Figure 8B).
There was no difference in thymus cellularity across groups
(Figure 8C).
We observed an increase in absolute counts of Treg cells (p =
0.030) (Figure 9B), CD4+ lymphocytes (p = 0.007; Figure 9E),
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FIGURE 9 | Regulatory T cells, helper T cells, and killer T cells in bronchoalveolar lavage fluid (BALF), lymph nodes, and thymus tissue. Quantification of
total CD4+CD25+Foxp3+ cells (first vertical line), CD4+ cells (second vertical line), and CD8+ cells (third vertical line) in BALF (A,D,G), lymph node (B,E,H), and
thymus tissue (C,F,I), respectively, of CTRL-DMSO, CTRL-BOS, SIL-DMSO, and SIL-BOS animals. White bars, DMSO; gray bars, BOS. Values are means + SD of 8
animals per group. *Significantly different from C-DMSO (p < 0.05). **Significantly different from SIL-DMSO (p < 0.05).
and CD8+ lymphocytes (p = 0.026; Figure 9H) in the lung-
draining lymph nodes of SIL-DMSO vs. CTRL-DMSO animals.
There was a significant reduction in absolute number of Treg (p
= 0.03; Figure 9B), CD4+ (p = 0.014; Figure 9E), and CD8+
cells (p = 0.016; Figure 9H) in SIL-BOS compared to SIL-
DMSO animals. No significant differences in the number of
these cells in BALF or thymus were observed between groups
(Figures 9A,C,D,F,G,I).
Lung Fibrosis
The percentage of collagen fibers quantified in lung parenchyma
was increased in SIL-DMSO compared to CTRL-DMSO animals
(p = 0.02; Figure 10A). In silicotic animals, treatment with
bosutinib reduced the percentage of collagen fibers as compared
to DMSO treatment alone (p = 0.04; Figure 10A). The amount
of collagen fibers within granuloma tissue did not differ between
the SIL-DMSO and SIL-BOS groups (p= 0.123; Figure 10B).
DISCUSSION
Under the conditions of this study, bosutinib therapy of silicotic
animals had a variety of positive effects, including reduction
in: (1) fraction area of collapsed alveoli and granuloma, as
well as in neutrophil and macrophage counts in lung tissue;
(2) M1 macrophages in alveolar septa and granuloma, (3) IL-
1β, TNF-α, IFN-γ, and TGF-β levels in lung homogenates, (4)
total cellularity, Treg, CD4+, and CD8+ populations in lung-
draining lymph nodes, and (5) collagen fiber content in lung
parenchyma. Additionally, lung mechanics improved and M2
macrophages increased in alveolar septa and granuloma. Our
in vitro experiment showed that bosutinib reduced expression
of iNOS and IL-12 and increased expression of IL-10, arginase,
MMP-9, and TIMP-1 in macrophages exposed to silica. To
the best of our knowledge, this was the first study to analyze
the potential therapeutic effects of bosutinib on lung function,
inflammation, and remodeling in experimental silicosis.
In the murine model used in the present study, silicosis
was induced by a single exposure to crystalline silica, which,
after 15 days, led to lung mechanical and histological changes
that resembled those of human silicosis (Faffe et al., 2001;
Maron-Gutierrez et al., 2011; Lopes-Pacheco et al., 2013). In
addition, we have decided to use a C57BL/6 mouse strain, which
is a prototypical Th1-type mouse strain. Additionally, when
compared to other mouse strains, C57BL/6 macrophages present
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FIGURE 10 | Collagen fibers. Representative photomicrographs (polarized light microscopy) of lung parenchyma and granuloma tissue stained with Picrosirius Red
(right panels). Collagen fibers are shown in orange. Original magnification 200×. Scale bars = 200 µm. Left panels depict collagen fiber content quantification in lung
parenchyma (upper panel, A) and granuloma (lower panel, B). White bar, DMSO; gray bar, BOS. Boxes show the interquartile (25–75%) range, whiskers encompass
the range (minimum–maximum), and horizontal lines represent median values of 8 animals per group. *Significantly different from C-DMSO (p < 0.05). **Significantly
different from SIL-DMSO (p < 0.05).
higher levels of TNF-α and IFN-γ and, higher phagocytic activity
when stimulated (Watanabe et al., 2004).
In our study, CTRL animals were treated with DMSO. Even
though DMSO may result in lung inflammation, pilot studies
compared saline with DMSO and found no significant differences
in lung mechanics and morphometry or collagen fiber content
between groups (Oliveira et al., 2015; Cruz et al., 2016; da
Silva et al., 2016). Mice exposed to silica exhibited higher Est,L
and 1P2,L values, which were associated with the presence of
silicotic granulomas, alveolar collapse, thickening of alveolar
septa, infiltration of inflammatory cells in lung parenchyma,
and collagen fiber deposition. The increase in airway resistive
pressure (1P1,L) may have been due to the greater number of
cells in the bronchi associated with areas of lumen obstruction
(Faffe et al., 2001; Borges et al., 2002;Maron-Gutierrez et al., 2011;
Lopes-Pacheco et al., 2013; Cruz et al., 2016). Bosutinib decreased
both Est,L and1P2,L likely due to reduction in alveolar collapse,
interstitial edema, thickening of alveolar septa, cell infiltration
and collagen fiber content, whereas 1P1,L did not change after
therapy which may be attributed to the presence of the silica
particle adhere to the airway and airway hyperreactivity (Ferreira
et al., 2013).
Silicosis is classically characterized by mononuclear cell
aggregation with mineral particles and fibrosis. Macrophages
are the key innate immune system cells implicated in this
response, and orchestrate the entire pathophysiology of silicosis.
Briefly, silica particles are phagocytized by macrophages that
are activated, thus inducing oxidative stress, mitochondrial
injury, lysosome injury, and apoptosis (Setoguchi et al., 1996;
Fubini and Hubbard, 2003). Silica particles induce the release of
metalloproteases, free radicals, and pro-inflammatory mediators,
such as: IL-1β and TNF-α through activation of the nuclear
factor (NF)-κB pathway (Rimal et al., 2005; Greenberg et al.,
2007), which is involved in the recruitment ofmore inflammatory
cells to the site of the lesion—including neutrophils, which are
involved in the lung fibrosis process (Maron-Gutierrez et al.,
2011).
Furthermore, lymphocytes (predominantly CD4+ T cells, but
also numerous CD8+ T cells and natural killer cells) are known
to be abundant in the lesions of silicosis (Davis et al., 2001).
In our study, silica-exposed mice exhibited accumulation of
lymphocytes in alveolar spaces, lung parenchyma, granuloma,
enlarged bronchial-associated lymphoid tissues, and thoracic
lymph nodes, which is consistent with this feature. Previous
studies showed that Th1 and Th2 cytokines are involved in
silicosis, but Th1/Th2 polarization during the development of
silicosis is still a matter of debate. Several evidences suggest each
plays a distinct role. Specifically, Th1 response is inflammation
is upregulated in the acute phase while Th2 cytokines have only
been associated with fibrosis in the later stages (Garn et al.,
2000). It might explain the increased levels of IFN-γ in lung
homogenates in SIL-DMSO animals. In addition, Treg cells play a
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crucial role in modulation of immune homeostasis by regulating
Th1/Th2 polarization, but their possible implication in silicosis
has been explored only in the past few years. Liu et al. suggested
that depletion of Tregs attenuated the progression of silica-
induced lung fibrosis, reduced Th1 response, and shifted the
Th1/Th2 balance toward a Th2 phenotype (Liu et al., 2014). In
our sample, bosutinib was able to reduce the number of Treg cells
and IFN-γ levels which might be associated with less collagen
deposition in lung parenchyma.
Several tyrosine kinase pathways have been found to play
essential roles in the pathophysiology of silicosis. At therapeutic
dosages, bosutinib, an ATP-competitive tyrosine kinase inhibitor,
inhibits the activity of Bcr-Abl and Src-family kinases including
Src, Yes, Fgr, Fyn, Lck, Lyn, Hck, and Blk. Bosutinib was first
approved to treat chronic myeloid leukemia in patients resistant
or intolerant to prior lines of therapy (Thomas and Brugge,
1997; Goldenberg, 2012). Besides its effect on malignant cells,
bosutinib also blocks several inflammatory cell pathways, since
tyrosine kinases are closely involved in a wide variety of signaling
pathways of the hematopoietic system, including those mediated
by receptors of specific antigens, integrin, cytokines, and toll-
like mediated receptors (Page et al., 2009). Thus, bosutinib
inhibits lymphocyte activation and proliferation and suppresses
neutrophil and macrophage activation and chemotaxis (Zarbock
and Ley, 2011; Futosi et al., 2012), due to its inhibition of Lck
(predominantly expressed in T cells), Blk (in B cells), Lyn and Fgr
(in myeloid cells), and Src, Yes, and Fyn (in leukocytes in general;
Thomas and Brugge, 1997). The dose of bosutinib chosen for the
present study (1 mg/kg) was based on pilot studies conducted
in our lab. The reduction of macrophage and neutrophil counts
in lung parenchyma and lymphocytes in lung-draining lymph
nodes effected by bosutinib in this study might be explained
by the ability of this compound to disrupt leukocyte adhesion,
activation, and migration (Zarbock and Ley, 2011).
Oxidative stress, generated either directly by silica particles or
indirectly by inflammatory cells, triggers activation of tyrosine
kinases that are involved in the dimerization and nuclear
translocation of NF-κB (Kang et al., 2006), which regulates genes
that control physiological processes including innate immune
response and inflammation (Di Giuseppe et al., 2009) and that
promote macrophage polarization toward the M1 phenotype
(Portaa et al., 2009). Bosutinib was able to reduceM1macrophage
and increase M2 macrophage counts in lung parenchyma and
granuloma tissue from silicotic mice in our sample. This suggests
that bosutinib might inhibit this signaling pathway, since NF-
κB activation in macrophages is Src-dependent (Kang et al.,
2006). M2 macrophages can resolve inflammation through
high endocytic clearance abilities; production of autocrine and
paracrine trophic factors; reduced pro-inflammatory cytokine
secretion (Wang et al., 2007); increased expression of arginase-1,
which inhibits the production of pro-inflammatory and oxidative
nitric oxide (Mosser, 2003); and enhanced expression of the
IL-1 receptor antagonist (which inhibits the effects of pro-
inflammatory IL-1), the mannose receptor, and chitinase-like 3
(Wilson et al., 2004).
The role of M2 macrophages in fibrosis is controversial.
They have been associated with fibrosis development, since their
numbers are increased in pulmonary fibrosis (Endo et al., 2003;
Boorsma et al., 2013). On the other hand, new evidence suggests
they may not be the cause but a consequence of fibrosis, more
specifically of a failed attempt to clear excess extracellular matrix
and thus trigger fibrosis resolution. In liver fibrosis models,
M2 macrophages were not required for development of fibrosis
(Herbert et al., 2004), but were shown to be important for its
resolution (Pesce et al., 2009; Weng et al., 2014). Furthermore,
secretion of TIMP-1 is involved in spontaneous resolution of liver
fibrosis by the combination of a net reduction and suppression
of apoptosis; conversely, downregulation of TIMP-1 has been
found to exacerbate liver injury and fibrosis (Yoshiji et al.,
2002). M2 macrophages have been shown to produce MMP-
9, which may contribute toward attenuation of fibrotic lesions
(Bourlier et al., 2008). In the context of lung fibrosis, Misson
et al. addressed the question of whether M2 macrophages were
associated with collagen fiber deposition in the lungs in a murine
model of single intratracheal instillation of silica particles. The
authors observed that the upregulation of M2-associated genes
such as arginase-1 mRNA was not associated with the severity of
lung fibrosis (Misson et al., 2004). Moreover, M2 macrophages
express different mannose receptors, also considered classical
M2 markers, which appear to be responsible for the uptake
of extracellular matrix components (Weng et al., 2014). In
a previous study by our group, we showed that dasatinib,
another tyrosine kinase inhibitor, increased M2 macrophage
counts and reduced collagen deposition in lung parenchyma
and granuloma (Cruz et al., 2016). Our results showed that
the antifibrotic effects of bosutinib might be explained by its
anti-inflammatory properties, by the antifibrotic effects of M2
macrophages, downregulation of Treg cells, reduced levels of
the pro-fibrotic mediator TGF-β and by direct pharmacological
inhibition of PTK, which is associated with profibrotic receptors
such as FAK (Reiske et al., 2000; Hauck et al., 2002; Bourlier et al.,
2008; Siesser et al., 2008; Lagares et al., 2012; Zhao et al., 2016).
In the present study, bosutinib reduced inflammation
and induced several hallmark features of regulatory-like
macrophages, subsequently decreasing lung fibrosis, in mice with
experimental silicosis. Whether other tyrosine kinase inhibitors
might exert similar effects remains unclear, as does their clinical
potential for this indication. As noted above, in a previous study
by our group (Cruz et al., 2016), the second-generation tyrosine
kinase inhibitor dasatinib was shown to be partially effective at
improving lung mechanics and reducing remodeling in a murine
model of silicosis. Clinically, dasatinib has been associated with
adverse events such as diarrhea, pleural effusion, and dyspnea
in patients with breast cancer and melanoma (Finn et al.,
2011; Kluger et al., 2011). Nintedanib (formerly known as BIBF
1120) is an intracellular inhibitor that targets multiple tyrosine
kinases. In a phase II trial patients with idiopathic pulmonary
fibrosis, nintedanib at a dose of 150mg twice daily reduced lung-
function decline and acute exacerbations, but several patients
discontinued treatment due to adverse effects (Richeldi et al.,
2011).
This study presents limitations: (1) bosutinib was
administered 15 days after silica administration, when the
disease was already established, but further studies are required
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evaluating the effects of bosutinib late in the course of disease;
and (2) we did not evaluate the impact of bosutinib on different
components of extracellular matrix (ECM), as well as MMP and
TIMPS in the lung, but focused on the main component of ECM
(collagen fiber) modified in silicosis (Hubbard et al., 2005).
CONCLUSIONS
In a manner consistent with its Src-family tyrosine-kinase
inhibition profile, bosutinib reduced inflammation in the
lung and lung-draining lymph nodes and mitigated fibrosis
in the lung parenchyma of mice subjected to induction
of experimental silicosis. Although, the precise mechanism
behind this effect remains unknown, this inhibitor may
represent an interesting alternative for treatment of fibrotic
diseases.
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